目的 探討丹參酮Ⅱ_A磺酸鈉注射液聯(lián)合鹽酸多奈哌齊片治療輕度血管性認(rèn)知障礙的臨床療效。方法 選取2015年9月—2017年9月重慶市人民醫(yī)院康復(fù)醫(yī)學(xué)科治療的104例輕度血管性認(rèn)知障礙患者作為研究對(duì)象，所有患者隨機(jī)分為對(duì)照組和治療組，每組各52例。對(duì)照組口服鹽酸多奈哌齊片，5 mg/次，1次/d；治療組在對(duì)照組治療的基礎(chǔ)上靜脈滴注丹參酮Ⅱ_A磺酸鈉注射液，40 mg丹參酮Ⅱ_A磺酸鈉注射液加入5%葡萄糖注射液250 mL中，1次/d。兩組患者療程為2周，治療4個(gè)療程后觀察其臨床療效。比較兩組患者治療前后的蒙特利爾認(rèn)知評(píng)估量表（MoCA）評(píng)分、簡(jiǎn)易智力狀態(tài)檢查量表（MMSE）評(píng)分、日常生活能力量表（ADL）評(píng)分和炎性因子水平。結(jié)果 治療后，治療組總有效率為96.15%，顯著高于對(duì)照組的76.92%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者M(jìn)oCA、MMSE評(píng)分均顯著升高，ADL評(píng)分顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組治療后MoCA、MMSE和ADL評(píng)分顯著優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清超敏C反應(yīng)蛋白（hs-CRP）、白細(xì)胞介素-6（IL-6）和腫瘤壞死因子-α（TNF-α）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組治療后炎癥因子水平顯著低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 丹參酮Ⅱ_A磺酸鈉注射液聯(lián)合鹽酸多奈哌齊片治療輕度血管性認(rèn)知障礙的療效顯著，能夠顯著提高患者的認(rèn)知能力和日常生活能力，改善血清炎性因子水平，且安全可靠，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Tanshinone Ⅱ_A Sulfonate Injection combined with Donepezil Hydrochloride Tablets in treatment of mild vascular cognitive impairment. Methods Patients (104 cases) with mild vascular cognitive impairment in Chongqing General Hospital from September 2015 to September 2017 were randomly divided into control and treatment groups, and each group had 52 cases. Patients in the control group were po administered with Donepezil Hydrochloride Tablets, 5 mg/time, once daily. Patients in the treatment group were iv administered with Tanshinone Ⅱ_A Sulfonate Injection on the basis of the control group, 40 mg added into 5% Glucose Injection 250 mL, once daily. Patients in two groups were treated for 2 weeks, and the clinical efficacy was observed after 4 courses of treatment. And the MoCA scores, MMSE scores, ADL scores, and serum inflammatory factors levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 96.15%, which was significantly higher than 76.92% in the control group, and there were differences between two groups (P<0.05). After treatment, the MoCA and MMSE scores in two groups were significantly increased, but ADL scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the MoCA, MMSE and ADL scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, levels of hs-CRP, IL-6, and TNF-αin two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Tanshinone Ⅱ_A Sulfonate Injection combined with Donepezil Hydrochloride Tablets has significant clinical efficacy in treatment of mild vascular cognitive impairment, can significantly improve the cognitive ability and daily living ability of patients, and improve the levels of serum inflammatory factors, and is safe and reliable, which has a certain clinical application value.